Source: Pharamceutical Technology

ReNetx: AXER-204 by ReNetX Bio for Chronic Spinal Cord Injury: Likelihood of Approval

AXER-204 is under clinical development by ReNetX Bio and currently in Phase II for Chronic Spinal Cord Injury.

Read full article »
ReNetx's Competitors | ReNetx's News | ReNetx's Financials
Stay up-to-date with the latest news on ReNetx
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Erika R. Smith's photo - CEO of ReNetx

CEO

Erika R. Smith

CEO Approval Rating

75/100

Read more
Stay up-to-date with the latest news on ReNetx